PGR and breast cancer: Our finding that Ano1 overexpression was associated with good prognosis in PR-positive or HER2-negative breast cancer patients following tamoxifen treatment suggests that Ano1 overexpression is a predictive factor for tamoxifen benefit in these subgroups of breast cancer patients.